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Clinics and pathology 
Disease 
Multiple myeloma (MM) is a malignant plasma cell 
proliferation 
Phenotype/cell stem origin 
Mature differentiated B-cell, but also with CD56 
expression, which is not found in normal plasma 
cell; CD38+, CD40+, CD138+. 
Epidemiology 
MM's annual incidence is 30/106; del(6q) is 
observed in about 2 to 5% of MM cases (i.e.: 5-
10% of cases with an abnormal karyotype). 
Clinics 
Bone pain; susceptibility to infections; renal failure; 
neurologic dysfunctions. 
Pathology 
MM staging:  
- stage I: low tumour cell mass; normal Hb; low 
serum calcium; no bone lesion; low monoclonal Ig 
rate;  
- stage II: fitting neither stage I nor stage II; 
- stage III: high tumour cell mass; low Hb and/or 
high serum calcium and/or advanced lytic bone 
lesions and/or high monoclonal Ig rate. 
Evolution 
MM can evolve towards plasma cell leukemia. 
Prognosis 
Prognosis (highly variable) is according to the 
staging and other parameters, of which are now the 
karyotypic findings: two distinct cytogenetic 
pattern have been reported, according to the 
chromosome number: 1- a hyperdiploid pattern, and  
2- a pattern of either pseudodiploidy, hypodiploidy 
or near-tetraploidy karyotypes; patients with the 
latter pattern appear to have a worse prognosis than 
patients with a hyperdiploid karyotype (med 
survival of 1.5 yr vs 3 yrs; p<0.04). del(6q) 




del(6q) are mainly so-called terminal deletions, 
with a variable breakpoint in q12, q15, q21, or q23; 
overall, the break occurs predominantly in 6q21. 
Genes involved and 
proteins 
Note 
del(6q) in MM cases encompass the 6q21 band: 
loss of this band suggests that the critical gene(s) 
might be a recessive tumour suppressor gene sitting 
in 6q21, which remains to be identified 
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